SBIR, STTR, and other federal funding applicants can request study plans, written estimates, and letters of interest. AGI Ventures will separately consider selected biotechnology programs for follow-on research support and investment.
YEMASSEE, SC / ACCESS Newswire / November 12, 2026 / Alpha Genesis, Inc. today announced an initiative to help biotechnology companies, academic investigators, and research institutions plan and budget preclinical studies for U.S. federal funding proposals. Applicants can work directly with Alpha Genesis scientists before submission to select a research model, define endpoints, and obtain a written scope, cost estimate, and projected timeline. Biotechnology companies seeking a partner for follow-on research can also apply separately to AGI Ventures, the company’s strategic investment division.
Alpha Genesis provides full-service preclinical research in rodent and nonhuman primate models, from study design and execution through data collection and reporting. The company supports proof-of-concept, pharmacokinetic, and biodistribution studies, as well as follow-on efficacy, dose-ranging, and toxicology studies, including GLP toxicology where appropriate. Alpha Genesis will reflect reduced pricing for qualifying studies in its written estimates.
“I love working with biotech founders and investigators while they’re still deciding what to put in a proposal,” said Xavier Westergaard, Ph.D., President and Chief Scientific Officer of Alpha Genesis. “One of the first things I ask is what result would change their next decision. If it comes down to whether a candidate reaches the target tissue, we can work through what to measure, when to sample, and what it will cost. By the time they submit, I want them to know what the study will tell them and when they can expect the data.”
Support for federal research proposals
For qualifying projects, Alpha Genesis will provide a letter of interest describing the proposed work and the company’s anticipated responsibilities if the project is funded. It can also provide facility and animal welfare documentation for applicants proposing Alpha Genesis as a U.S. research performance site. The company maintains a Domestic Animal Welfare Assurance with the NIH Office of Laboratory Animal Welfare (D16-00387), holds AAALAC International accreditation and USDA licensure, and conducts animal research under IACUC oversight.
Upcoming 2027 submission dates include January 5 and April 5 for the NIH parent SBIR and STTR opportunities, February 5 for new applications under the NIH parent R01 announcement, February 16 for new applications under the NIH parent R21 announcement, and March 4 and July 7 for NSF’s SBIR/STTR solicitation NSF 26-510. ARPA-H Mission Office Innovative Solution Openings accept submissions on a rolling basis. Department of Defense research deadlines vary by solicitation.
Follow-on research through AGI Ventures
Alpha Genesis launched AGI Ventures in September 2026 with an initial $50 million commitment in research services and strategic investments for selected biotechnology companies. A company preparing a federally funded proof-of-concept study can engage Alpha Genesis on a fee-for-service basis and separately ask AGI Ventures to evaluate a subsequent study tied to a financing, licensing, or development milestone. Arrangements for selected companies may include research credits, deferred study fees, or strategic investment, with terms negotiated separately.
Request preclinical study support
Applicants can request a study quote, email info@alphagenesisinc.com, or call +1 (843) 589-5190. Include the funding opportunity, submission deadline, and a brief, nonconfidential description of the question the study needs to answer. Indicate whether you need a written estimate, a letter of interest, or both.
Biotechnology companies interested in follow-on research support or strategic investment can apply separately to AGI Ventures. Applications are reviewed on a rolling basis.
About Alpha Genesis
Alpha Genesis, Inc. is a full-service preclinical contract research organization conducting GLP and non-GLP studies in rodent and nonhuman primate models. Its capabilities span early pharmacology through IND-enabling development. AGI Ventures is the company’s strategic investment and venture-development division. alphagenesisinc.com
Media contact
Xavier Westergaard, Ph.D.
President, Alpha Genesis, Inc.
xwestergaard@alphagenesisinc.com
+1 (843) 589-5190
SOURCE: Alpha Genesis, Inc.
View the original press release on ACCESS Newswire
Media gallery
